Moderna, Inc. announced the first participant has been dosed in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2 modified for the expansion of regulatory T cells.
[Moderna, Inc.]
Sorry, but the selected Zotpress account can't be found.
